1-20 of 29
Nicholas Keen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 5301: Tumor-targeted activation of CD137 using Bicycles: New insights into mechanism of action and discovery of BT7455, a clinical candidate for the treatment of EphA2-expressing cancers

Johanna Lahdenranta, Kristen Hurov, Heather Cohen, Lia Luus, Cara Bray, Peter Brown, Anna Devlen, Carly Campbell, Matthew Gray, Mike Kelly, Gemma Mudd, Punit Upadhyaya, Sailaja Battula, Kelvin Zhang, Anne-Sophie Dugast, Kevin McDonnell, Phil Brandish, Nicholas Keen
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 5301.
https://doi.org/10.1158/1538-7445.AM2024-5301
Published: 22 March 2024
View article titled, Abstract 5301: Tumor-targeted activation of CD137 using <em>Bicycles</em>: New insights into mechanism of action and discovery of BT7455, a clinical candidate for the treatment of EphA2-expressing cancers
Journal Articles

Abstract 1340: Modulation of the natural killer cell immune response to tumor with a synthetic tumor -immune cell agonist, NK-TICA™

Fay Dufort, Tucker Ezell, Alexandra Rezvaya, Kathleen Ho, Christopher Leitheiser, Philip Brandish, Kevin McDonnell, Nicholas Keen
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 1340.
https://doi.org/10.1158/1538-7445.AM2024-1340
Published: 22 March 2024
View article titled, Abstract 1340: Modulation of the natural killer cell immune response to tumor with a synthetic tumor -immune cell agonist, NK-TICA™
Journal Articles

Abstract 5807: Bicycle Toxin Conjugates®for the treatment of solid tumors

Stephen J. Walsh, Johanna Lahdenranta, Philip Huxley, Gemma Mudd, Gavin Bennett, Amy Brown, Katerine an Rietschoten, Liuhong Chen, Heather Scott, Gabriella Ivanova-Berndt, Katarzyna Dzionek, Mike Rigby, Olga Burenkova, Phil Jeffrey, Paul Beswick, Michael Skynner, Nicholas Keen
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 5807.
https://doi.org/10.1158/1538-7445.AM2024-5807
Published: 22 March 2024
View article titled, Abstract 5807: Bicycle Toxin Conjugates®for the treatment of solid tumors
Journal Articles

Abstract 1806: Modulation of natural killer cell immune response to tumor with novel synthetic tumor -immune cell agonist, NK-TICA(r)

Fay Dufort, Christopher J. Leitheiser, Kathleen Ho, Tucker Ezell, Alexandra Rezvaya, Peter Brown, Liuhong Chen, Philip Brandish, Kevin McDonnell, Michael Skynner, Nicholas Keen
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 1806.
https://doi.org/10.1158/1538-7445.AM2023-1806
Published: 04 April 2023
View article titled, Abstract 1806: Modulation of natural killer cell immune response to tumor with novel synthetic tumor -immune cell agonist, NK-TICA(r)
Journal Articles

Abstract 1832: EphA2-dependent CD137 agonism and anti-tumor efficacy by BT7455, a Bicycle tumor-targeted immune cell agonist®

Lia Luus, Kristen Hurov, Johanna Lahdenranta, Chinmayee Shah, Anna Devlen, Julia Kristensson, Peter Brown, Cara Bray, Heather Cohen, Carly Campbell, Gemma Mudd, Punit Upadhyaya, Kevin McDonnell, Hongmei Xu, Phil Jeffrey, Philip E. Brandish, Nicholas Keen
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 1832.
https://doi.org/10.1158/1538-7445.AM2023-1832
Published: 04 April 2023
View article titled, Abstract 1832: EphA2-dependent CD137 agonism and anti-tumor efficacy by BT7455, a <em>Bicycle</em> tumor-targeted immune cell agonist<sup>®</sup>
Journal Articles

Abstract 1826: In vivo evaluation of NK-TICA®, a novel Bicycle® tumor-targeted immune cell agonist (TICA) designed to engage NK cells

Lukas Stanczuk, Johanna Lahdenranta, Fay J. Dufort, Christopher J. Leitheiser, Punit Upadhyaya, Philip E. Brandish, Nicholas Keen
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 1826.
https://doi.org/10.1158/1538-7445.AM2023-1826
Published: 04 April 2023
View article titled, Abstract 1826: <em>In vivo</em> evaluation of NK-TICA®, a novel Bicycle® tumor-targeted immune cell agonist (TICA) designed to engage NK cells
Journal Articles

Abstract 4230: Modeling the cDC1 ex vivo and in vitro: Development and comparison of a conventional dendritic cell culture system for industry

Laura L. Goodfield, Johanna Lahdenranta, Heather Scott, Tamera Ashworth, Lia Luus, Anna F. Licht, Kevin McDonnell, Phil Brandish, Nicholas Keen
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 4230.
https://doi.org/10.1158/1538-7445.AM2022-4230
Published: 15 June 2022
View article titled, Abstract 4230: Modeling the cDC1 <em>ex vivo</em> and <em>in vitro</em>: Development and comparison of a conventional dendritic cell culture system for industry
Journal Articles

Abstract 4233: Generation of a Bicycle NK-TICA™, a novel NK cell engaging molecule designed to induce targeted tumor cytotoxicity

Fay J. Dufort, Christopher J. Leitheiser, Gemma Mudd, Julia Kristensson, Alexandra Rezvaya, Katie Gaynor, Sandra Uhlenbroich, Liudvikas Urbonas, Heather Scott, Liuhong Chen, Helen Harrison, Michael Skynner, Kevin McDonnell, Philip E. Brandish, Nicholas Keen
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 4233.
https://doi.org/10.1158/1538-7445.AM2022-4233
Published: 15 June 2022
View article titled, Abstract 4233: Generation of a <em>Bicycle</em> NK-TICA™, a novel NK cell engaging molecule designed to induce targeted tumor cytotoxicity
Journal Articles

Abstract 1976: Development of a CD137 receptor occupancy assay to support the phase I/II study of BT7480, a Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA®)

Heather Cohen, Drasti Kanakia, Johanna Lahdenranta, Punit Upadhyaya, Kristen Hurov, Julia Kristensson, Chintan Jobaliya, Greg Bannish, Adam Cotty, Kevin McDonnell, Sandra Hirschberg, Phil Brandish, Sebastien Hazard, Dominic Smethurst, Nicholas Keen, Stephen J. Blakemore
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1976.
https://doi.org/10.1158/1538-7445.AM2022-1976
Published: 15 June 2022
View article titled, Abstract 1976: Development of a CD137 receptor occupancy assay to support the phase I/II study of BT7480, a <em>Bicycle</em> tumor-targeted immune cell agonist™ (<em>Bicycle</em> TICA®)
Journal Articles

Abstract 1728: Nectin-4-dependent immune cell stimulation and anti-tumor efficacy by BT7480, a Nectin-4/CD137 Bicycle®tumor-targeted immune cell agonist (TICA™)

Kristen Hurov, Johanna Lahdenranta, Punit Upadhyaya, Drasti Kanakia, Elizabeth Repash, Fanglei You, Jun Ma, Eric Haines, Heather Cohen, Kevin McDonnell, Philip E. Brandish, Phil Jeffrey, Nicholas Keen
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1728.
https://doi.org/10.1158/1538-7445.AM2021-1728
Published: 01 July 2021
View article titled, Abstract 1728: Nectin-4-dependent immune cell stimulation and anti-tumor efficacy by BT7480, a Nectin-4/CD137 <em>Bicycle</em>®tumor-targeted immune cell agonist (TICA™)
Journal Articles

Abstract 1724: Microinjection of Nectin-4/CD137 tumor-targeted immune cell agonist (TICA™) activates the local tumor microenvironment

Johanna Lahdenranta, Stephen J. Blakemore, Kristen Hurov, Marc O. Grenley, Punit Upadhyaya, Carly Campbell, Elizabeth Repash, Eric Haines, Philip E. Brandish, Richard A. Klinghoffer, Nicholas Keen
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1724.
https://doi.org/10.1158/1538-7445.AM2021-1724
Published: 01 July 2021
View article titled, Abstract 1724: Microinjection of Nectin-4/CD137 tumor-targeted immune cell agonist (TICA™) activates the local tumor microenvironment
Journal Articles

Abstract 1319: Rapid accumulation of cytotoxic payload in tumor tissue drives BT5528 activity in tumor models

Johanna Lahdenranta, Gavin Bennett, Philip Huxley, Gemma Mudd, Punit Upadhyaya, Phil Jeffrey, Nicholas Keen
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1319.
https://doi.org/10.1158/1538-7445.AM2021-1319
Published: 01 July 2021
View article titled, Abstract 1319: Rapid accumulation of cytotoxic payload in tumor tissue drives BT5528 activity in tumor models
Journal Articles

Abstract 5552: BT7480, a novel fully synthetic tumor-targeted immune cell agonist (TICATM) induces tumor localized 4-1BB agonism

Kristen Hurov, Punit Upadhyaya, Johanna Lahdenranta, Jessica Kublin, Jun Ma, Elizabeth Repash, Marianna Kleyman, Julia Kristensson, Liuhong Chen, Eric Haines, Sailaja Battula, Kevin McDonnell, Nicholas Keen
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 5552.
https://doi.org/10.1158/1538-7445.AM2020-5552
Published: 15 August 2020
View article titled, Abstract 5552: BT7480, a novel fully synthetic tumor-targeted immune cell agonist (TICA<sup>TM</sup>) induces tumor localized 4-1BB agonism
Journal Articles

Abstract 6703: A fully synthetic EphA2/4-1BB tumor-targeted immune cell agonist (TICATM) induces tumor localized 4-1BB agonism

Sailaja Battula, Gemma Mudd, Punit Upadhyaya, Julia Kristensson, Marianna Kleyman, Elizabeth Repash, Jessica Kublin, Jun Ma, Eric Haines, Kristen Hurov, Liuhong Chen, Johanna Lahdenranta, Paul Beswick, Kevin McDonnell, Nicholas Keen
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 6703.
https://doi.org/10.1158/1538-7445.AM2020-6703
Published: 15 August 2020
View article titled, Abstract 6703: A fully synthetic EphA2/4-1BB tumor-targeted immune cell agonist (TICA<sup>TM</sup>) induces tumor localized 4-1BB agonism
Journal Articles

Abstract 3257: Activation of CD137 using multivalent and tumor targeted Bicyclic peptides

Kristen E. Hurov, Punit Upadhyaya, Jessica Kublin, Xueyuan Zhou, Julia Kristensson, Rachid Lani, Gemma Mudd, Katerine van Rietschoten, Frank An, Johanna Lahdenranta, Liuhong Chen, Gavin Bennett, Kevin McDonnell, Peter Park, Nicholas Keen
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 3257.
https://doi.org/10.1158/1538-7445.AM2019-3257
Published: 01 July 2019
View article titled, Abstract 3257: Activation of CD137 using multivalent and tumor targeted Bicyclic peptides
Journal Articles

Abstract 4479: BT8009: A bicyclic peptide toxin conjugate targeting Nectin-4 (PVRL4) displays efficacy in preclinical tumor models

Mike Rigby, Paul Beswick, Gemma Mudd, Katerine Van Rietschoten, Liuhong Chen, Sophie M. Watcham, Heather Allen, Amy Brown, Helen Harrison, Gavin Bennett, Phil Jeffrey, Peter U. Park, Maria Koehler, Nicholas Keen
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 4479.
https://doi.org/10.1158/1538-7445.AM2019-4479
Published: 01 July 2019
View article titled, Abstract 4479: BT8009: A bicyclic peptide toxin conjugate targeting Nectin-4 (PVRL4) displays efficacy in preclinical tumor models
Journal Articles

Abstract 4481: BT5528, an EphA2-targeting Bicycle Toxin Conjugate (BTC): Profound efficacy without bleeding and coagulation abnormalities in animal models

Gavin S. Bennett, Amy Brown, Gemma Mudd, Johanna Lahdenranta, Nicholas Keen
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 4481.
https://doi.org/10.1158/1538-7445.AM2019-4481
Published: 01 July 2019
View article titled, Abstract 4481: BT5528, an EphA2-targeting Bicycle Toxin Conjugate (BTC): Profound efficacy without bleeding and coagulation abnormalities in animal models
Journal Articles

Abstract 5854: BT5528, a Bicycle Toxin Conjugate targeting EphA2 has potent anti-tumor activity without bleeding or coagulation abnormalities in preclinical models

Gavin Bennett, Philip Huxley, Amy Brown, Gemma Mudd, Peter U. Park, Nicholas Keen
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 5854.
https://doi.org/10.1158/1538-7445.AM2018-5854
Published: 01 July 2018
View article titled, Abstract 5854: BT5528, a Bicycle Toxin Conjugate targeting EphA2 has potent anti-tumor activity without bleeding or coagulation abnormalities in preclinical models
Journal Articles

Abstract DDT01-04: Pharmacological profile and anti-tumor properties of LXH254, a highly selective RAF kinase inhibitor

Darrin D. Stuart, Wenlin Shao, Yuji Mishina, Yun Feng, Giordano Caponigro, Vesselina G. Cooke, Stacey Rivera, Fang Shen, Joshua Korn, Lesley A. Mathews Griner, Giselle Nishiguchi, Benjamin Taft, Lifeng Wan, Sharadha Subramanian, Yan Lou, Lina Setti, Matthew Burger, Victor Tamez, Alice Rico, Robert Aversa, John Tellew, Jacob R. Haling, Valery Polyakov, Amy Lambert, Richard Zang, Ann Van Abbema, Mohamad Hekmat-Nejad, Payman Amiri, Mallika Singh, Nicholas Keen, Michael P. Dillon, Emma Lees, William R. Sellers, Savithri Ramurthy
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): DDT01-04.
https://doi.org/10.1158/1538-7445.AM2018-DDT01-04
Published: 01 July 2018
View article titled, Abstract DDT01-04: Pharmacological profile and anti-tumor properties of LXH254, a highly selective RAF kinase inhibitor
Journal Articles

Abstract 5855: Bicycle Drug Conjugates targeting EphA2 for the treatment of solid tumors: Discovery and selection of BT5528

Gavin Bennett, Philip Huxley, Amy Brown, Gemma Mudd, Katerine van Rietschoten, Silvia Pavan, Liuhong Chen, Sophie M. Watcham, Peter U. Park, Nicholas Keen
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 5855.
https://doi.org/10.1158/1538-7445.AM2018-5855
Published: 01 July 2018
View article titled, Abstract 5855: Bicycle Drug Conjugates targeting EphA2 for the treatment of solid tumors: Discovery and selection of BT5528